<p>Dry age-related macular degeneration (AMD) is a common eye condition that affects the macula, the central part of the retina responsible for sharp, detailed vision. It is considered complicated when factors such as advanced retinal damage, genetic predisposition, or the presence of other health conditions make the disease more difficult to manage or increase the risk of severe vision loss. Symptoms of dry AMD typically include gradual blurring of central vision, difficulty seeing in low light, and a blind spot in the center of vision. Over time, the condition can worsen, leading to significant visual impairment.</p>
<p>Treatment for dry AMD primarily focuses on slowing the progression of the disease, as there is currently no cure. The most common approach involves nutritional supplements containing high doses of vitamins and minerals, which have been shown to reduce the risk of progression in some individuals. Lifestyle changes, such as smoking cessation and a healthy diet rich in leafy greens and omega-3 fatty acids, can also help manage the disease. Regular eye exams are essential for monitoring disease progression and detecting any signs of wet AMD, a more severe form of the condition. While dry AMD cannot be reversed, early detection and appropriate management are key to preserving remaining vision and maintaining quality of life.</p>
<h2><strong>Dry Age Macular Degeneration Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Dry Age Macular Degeneration in 7MM from 2020 to 2034 is segmented as:-</p>
<ul>
<li>Total prevalent cases</li>
<li>Stage-specific prevalent cases&nbsp;</li>
<li>Total prevalent cases of geographic atrophy</li>
<li>Total prevalent cases of&nbsp;</li>
<li>Total diagnosed prevalent cases of&nbsp;</li>
<li>Age-specific cases of early and intermediate AMD</li>
<li>Age-specific cases of geographic atrophy</li>
<li>Geographic atrophy cases by visual impairment&nbsp;</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/dry-age-macular-degeneration-epidemiology-forecast"><span style="text-decoration: underline;"><strong>Dry Age Macular Degeneration Epidemiology</strong></span></a></h2>
<ul>
<li>Total prevalent cases of AMD in the 7MM are estimated at ~68 million.</li>
<li>The United States accounted for 31% of these cases.</li>
<li>In Japan, individuals aged 85+ contributed to 40% of total geographic atrophy cases.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/dry-age-macular-degeneration-market"><span style="text-decoration: underline;"><strong>Dry Age Macular Degeneration Market</strong></span></a></h2>
<p>The Dry Age Macular Degeneration market size in the 7MM was around USD 1.3 billion in 2023.</p>
<h2>Dry Age-Related Macular Degeneration Market Drivers</h2>
<ul>
<li>Diverse pipeline with peptide derivatives, antibodies, gene therapies, and stem cell treatments targeting key pathways.</li>
<li>Untapped dry AMD market offers significant opportunities similar to wet AMD.</li>
<li>Advancements in therapies like cell replacement and HtrA inhibition boost research.</li>
<li>Growing interest in novel treatments drives innovation.</li>
</ul>
<h2>Dry Age-Related Macular Degeneration Market Barriers</h2>
<ul>
<li>Lack of validated clinical endpoints delays therapy progress.</li>
<li>High costs of advanced therapies limit access and reimbursement.</li>
<li>Disease complexity complicates treatment and diagnostics.</li>
<li>Limited awareness and absence of approved therapies hinder early intervention.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight"><span style="text-decoration: underline;"><strong>Dry Age Macular Degeneration Emerging Drugs</strong></span></a></h2>
<p>The emerging drugs of the Dry Age Macular Degeneration market are</p>
<ul>
<li>Iptacopan</li>
<li>Elamipretide</li>
<li>IONIS-FB-LRx</li>
</ul>
<p>And others.</p>
<h2><strong>Dry Age Macular Degeneration Key Players</strong></h2>
<p>The key players in the Dry Age Macular Degeneration market are</p>
<ul>
<li>Novartis</li>
<li>Stealth BioTherapeutics</li>
<li>Ionis Pharmaceuticals/Roche</li>
</ul>
<p>And others.</p>

Dry Age Macular Degeneration Market

Dry Age Macular Degeneration Market Iinfographic

Dry Age Macular Degeneration Market Infographic

Dry Age Macular Degeneration Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.